Abstract
BackgroundTumor cells exploit immune checkpoints to evade immune detection and hinder immune cell activation. Despite the clinical implications of immune checkpoint blockade, resistance remains a challenge. Axl, a receptor tyrosine...
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
